CanBas Co

CanBas Co Asset Growth

The Year-over-Year Total Asset Growth of CanBas Co (4575.T) as of Oct 18, 2026 is -41.75 %. In the previous year, Year-over-Year Total Asset Growth was 25.37 % — a change of -264.57% (lower).

Asset Growth

-41.75 %

YoY

-264.57%

Last updated:

Year-over-Year Total Asset Growth of CanBas Co is 2026 -41.75 % . Year-over-Year Total Asset Growth of CanBas Co was 2025 25.37 % . It decreases by -264.57% lower compared to the previous year.

The CanBas Co Asset Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Asset Growth
Date
Asset Growth
Jan 1, 2019
51.37 JPY
Jan 1, 2020
44.31 JPY
Jan 1, 2021
2.56 JPY
Jan 1, 2022
-38.97 JPY
Jan 1, 2023
163.81 JPY
Jan 1, 2024
16.63 JPY
Jan 1, 2025
25.37 JPY
Jan 1, 2026
-41.75 JPY
The CanBas Co Asset Growth history
YEARAsset GrowthYoY
-41.75 %-264.57%
25.37 %+52.56%
16.63 %-89.85%
163.81 %-520.36%
-38.97 %-1,622.89%
2.56 %-94.23%
44.31 %-13.74%
51.37 %-222.96%
-41.78 %-1,653.85%
2.69 %-187.72%
-3.07 %-102.03%
151.05 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CanBas Co Stock analysis

What does CanBas Co do? CanBas Co Ltd is a biotechnology company based in Numazu-shi, Japan, operating within the healthcare sector. The company has a small team of 12 employees and went public on September 17, 2009, with its ticker listed as 4575.T and ISIN JP3244570002. Its primary focus is on anticancer drug discovery research, which includes developing drug discovery concepts, selecting candidate compounds through method-based approaches, conducting simple animal studies, and analyzing basic data on anticancer drug candidates entering development. Additionally, CanBas engages in early clinical development activities, such as preclinical studies required before submitting applications for clinical trials and conducting the initial phases of clinical trials. The company maintains a website at https://www.canbas.co.jp/ for further information. CanBas operates as a private entity with a minimal workforce, emphasizing research and development in the early stages of anticancer drug development. It does not provide details on specific products, acquisitions, or financial figures beyond its IPO date and employee count. The company's headquarters are located in Numazu-shi, Shizuoka Prefecture, Japan, and it is listed on the Tokyo Stock Exchange. Its operations are centered around foundational research in oncology, aiming to contribute to the discovery and development of new anticancer treatments. CanBas Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CanBas Co stock

Year-over-Year Total Asset Growth of CanBas Co is -41.75 % in 2026.

On Eulerpool you can find the complete historical development of Year-over-Year Total Asset Growth CanBas Co since 2006 – with annual values, charts, and detailed analysis.

Asset growth measures the percentage change in total assets. Rapid asset growth may indicate expansion but can also correlate with lower future returns.

To evaluate Year-over-Year Total Asset Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Total Asset Growth.

Year-over-Year Total Asset Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Total Asset Growth's CanBas Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — CanBas Co

All Key Metrics — CanBas Co